VA-CIG Regimen for Previously Untreated Acute Myeloid Leukemia: A Multicenter Prospective Single-Arm Trial

NCT07514832 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

48

Enrollment

OTHER

Sponsor class

Conditions

AML (Acute Myeloid Leukemia)

Interventions

DRUG: Venetoclax, Azacitidine, Cytarabine, Idarubicin, G-CSF

Sponsor

Beijing 302 Hospital